AVTX

13.35

3.96% -0.55

Pre-mercato: 13.70 0.35 +2.62%

Avalo Therapeutics Inc (AVTX)

Panoramica Notizia Cronologia dei prezzi Financials Perché AVTX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$13.90

Aprire:

$14

Volume 24 ore:

497.88K

Relative Volume:

0.82

Capitalizzazione di mercato:

$304.23M

Reddito:

$59,000

Utile/perdita netta:

$-78.26M

Rapporto P/E:

-2.1898

EPS:

-6.0964

Flusso di cassa netto:

$-51.46M

1 W Prestazione:

-7.36%

1M Prestazione:

-15.51%

6M Prestazione:

-3.96%

1 anno Prestazione:

+172.45%

Intervallo 1D:

$13.34

$14.14

Intervallo di 1 settimana:

$13.15

$14.80

Portata 52W:

$3.39

$20.72

Avalo Therapeutics Inc Stock (AVTX) Company Profile

Nome

Avalo Therapeutics Inc

Settore

Healthcare (1112)

Industria

Biotechnology (621)

Telefono

410-522-8707

Indirizzo

1500 LIBERTY RIDGE DRIVE, WAYNE

Dipendente

Cinguettio

Prossima data di guadagno

2026-03-19

Ultimi documenti SEC

AVTX's Discussions on Twitter

Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AVTX Avalo Therapeutics Inc	13.35	316.76M	59,000	-78.26M	-51.46M	-6.0964
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-09	Iniziato	Wolfe Research	Outperform
2026-04-06	Iniziato	Citizens	Mkt Outperform
2026-02-02	Iniziato	Guggenheim	Buy
2025-12-18	Iniziato	Mizuho	Outperform
2025-09-17	Reiterato	H.C. Wainwright	Buy
2025-09-05	Iniziato	TD Cowen	Buy
2025-08-15	Iniziato	Cantor Fitzgerald	Overweight
2025-06-02	Ripresa	H.C. Wainwright	Buy
2025-03-25	Iniziato	Jefferies	Buy
2025-03-25	Iniziato	Stifel	Buy
2025-02-28	Iniziato	Piper Sandler	Overweight
2025-02-21	Iniziato	Wedbush	Outperform
2024-12-19	Iniziato	BTIG Research	Buy
2024-10-24	Iniziato	H.C. Wainwright	Neutral
2024-04-16	Aggiornamento	Oppenheimer	Perform → Outperform
2021-09-24	Iniziato	RBC Capital Mkts	Outperform

Mostra tutto

Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie

Apr 13, 2026

AVTX Reiterated by BTIG -- Price Target Maintained at $40 - GuruFocus

Apr 13, 2026

Short Squeeze: Can Avalo Therapeutics Inc grow without external funding2026 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Wall Street analysts predict an 113.34% upside in Avalo Therapeutics (AVTX): Here's what you should know - MSN

Apr 12, 2026

Apr 10, 2026

Breakout Move: Is Avalo Therapeutics Inc a potential multi baggerWeekly Profit Analysis & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Apr 10, 2026

Avalo Therapeutics (NASDAQ: AVTX) sets 2026 virtual meeting and ESPP changes - Stock Titan

Apr 10, 2026

Death Cross: Will Avalo Therapeutics Inc be affected by tariffsWeekly Loss Report & Daily Profit Focused Screening - baoquankhu1.vn

Apr 10, 2026

Wolfe Research initiates coverage of Avalo Therapeutics (AVTX) with outperform recommendation - MSN

Apr 10, 2026

Apr 09, 2026

AVTX: Wolfe Research Initiates Coverage with 'Outperform' Rating - GuruFocus

Apr 09, 2026

Apr 08, 2026

Wolfe Research Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $48 - Moomoo

Apr 08, 2026

Mittie Doyle Sells 3,970 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock - MarketBeat

Apr 08, 2026

Aug Closing: Is Avalo Therapeutics Inc undervalued by DCF analysis2026 Weekly Recap & Daily Chart Pattern Signal Reports - baoquankhu1.vn

Apr 08, 2026

Avalo Therapeutics: chief medical officer Doyle Mittie sells $71k in AVTX - Investing.com Canada

Apr 08, 2026

Avalo Therapeutics (AVTX) CMO exercises options, sells 3,970 shares in 10b5-1 trades - Stock Titan

Apr 08, 2026

Apr 07, 2026